Download Handout: https://bit.ly/3neTrOC

Methylene blue is reemerging as a hot topic in compounding, as practitioners are currently prescribing it for many conditions and disease states. Learn more about how this old chemical is shining a new light for patients struggling with:

• Mitochondrial dysfunction
• Long COVID symptoms
• Alzheimer’s disease
• Autism
• Depression
• Neurodegenerative diseases
• And more

PCCA Clinical Services Manager Sara Hover, RPh, FAARM, will discuss the benefits of methylene blue and clinical considerations for patients who are (and who are not) candidates for this therapy.

Speaker:
• Sara Hover, RPh, FAARM, PCCA Clinical Services Manager